Lymph Node Excision, Neoadjuvant Therapy, Ovarian Cancer, Postoperative Complications
Conditions
Keywords
Advanced epithelial ovarian cancer, Lymphadenectomy, Neoadjuvant chemotherapy, Interval debulking surgery, Prognosis, Postoperative complication
Brief summary
The study aims to investigate the prognostic and postoperative complication relevance of lymphadenectomy in advanced epithelial ovarian cancer patients who received neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS). The main question it aims to answer is: Does systematic lymphadenectomy during interval debulking surgery have a significant impact on survival in patients with advanced epithelial ovarian cancer who have received neoadjuvant chemotherapy? The progression-free survival (PFS), overall survival (OS), and postoperative complication were compared between the lymphadenectomy and no lymphadenectomy groups to answer the question.
Detailed description
The study aims to investigate the prognostic and postoperative complication relevance of lymphadenectomy in advanced epithelial ovarian cancer patients who received neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS). The study included patients with histologically confirmed advanced epithelial ovarian cancer who received IDS at seven tertiary hospitals in China from 2006 to 2021. The progression-free survival (PFS), overall survival (OS), and postoperative complication were compared between the lymphadenectomy and no lymphadenectomy groups. Propensity score matching (PSM) and overlapping weight (OW) analyses were performed to minimize selection bias.
Interventions
PROCEDURElymphadenectomy
Systematic pelvic and para-aortic lymphadenectomy during IDS in lymphadenectomy group
Sponsors
Tongji Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Healthy volunteers
No
Inclusion criteria
1. Consecutive patients with advanced epithelial ovarian cancer (stage IIB-IV, according to the International Federation of Gynecology and Obstetrics (FIGO) 2014); 2. Patients who underwent NACT followed by IDS.
Exclusion criteria
1. Patients with early-stage ovarian cancer (FIGO stage I-IIA); 2. Patients only receiving primary debulking surgery (PDS) as initial treatment without NACT; 3. Histological subtypes other than advanced epithelial ovarian cancer; 4. Patients with unclear sites of lymphadenectomy and non-compliant systematic lymphadenectomy that not include pelvic and/or para-aortic lymph nodes.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (OS) | From the initial diagnosis to the occurrence of recurrence, progression, death, or the latest follow-up, whichever came first, until February 10, 2021, an average of 5 years | Overall survival (OS) was described as the duration from the date of diagnosis to the date of death from any cause or the last follow-up date. |
| Progression free survival (PFS) | From the initial diagnosis to the occurrence of recurrence, progression, death, or the latest follow-up, whichever came first, until February 10, 2021, an average of 3 years | The progression-free survival (PFS) was defined as the duration from the initial diagnosis to the occurrence of recurrence, progression, death, or the latest follow-up, whichever came first. |
Countries
China
Outcome results
None listed